Loading
India's 2012 compulsory licence on sorafenib cut its price by about 97% and its 2019 cap on trade margins lowered the shelf price of 42 cancer drugs; voluntary licences through a patent pool would achieve the same without a fight.
In 2012 India's Controller General of Patents granted Natco a compulsory licence to make sorafenib at a fraction of Bayer's price with a 6% royalty, the first for a cancer drug. In 2019 the National Pharmaceutical Pricing Authority capped trade margins on 42 non-scheduled anticancer drugs at 30%, cutting retail prices. The Medicines Patent Pool has since signed its first oncology licences. A standing voluntary-licensing route for essential cancer medicines, with tiered pricing agreed in advance, would give manufacturers certainty and low-income countries generic prices years before patent expiry.
Shares WHO Essential Medicines List for cancer, World Health Organization Cancer Programme, Imatinib, Prices and value.
Shares Sorafenib, Secrecy and intellectual property block collaboration, Imatinib, Prices and value.
Shares Secrecy and intellectual property block collaboration, Imatinib, Prices and value.
Shares WHO Essential Medicines List for cancer, World Health Organization Cancer Programme, Secrecy and intellectual property block collaboration, Prices and value.
Shares WHO Essential Medicines List for cancer, Secrecy and intellectual property block collaboration, Imatinib, Prices and value.
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.